Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naval Daver

Showing results (221-230 of 436) with videos related to

Pageof 44
Sort By:
American Journal of Hematology|January 23, 2016
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemiaNicholas J Short, Hagop M Kantarjian, Elias J Jabbour, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 15, 2020
Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid LeukemiaFarhad Ravandi, Sherry Pierce, Guillermo Garcia-Manero, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2014
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemiaAlfonso Quintás-Cardama, Naval Daver, Hawk Kim, et al.
American Journal of Hematology|April 13, 2019
Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blastsPaolo Strati, Guillermo Garcia-Manero, Chong Zhao, et al.
American Journal of Hematology|August 25, 2015
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decadeTalha Badar, Hagop M Kantarjian, Graciela M Nogueras-Gonzalez, et al.
British Journal of Haematology|June 16, 2017
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemiaNicholas J Short, Hagop Kantarjian, Elias Jabbour, et al.
American Journal of Hematology|January 25, 2013
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control studyElias Jabbour, Michael S Mathisen, Guillermo Garcia-Manero, et al.
Haematologica|October 27, 2018
CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemiaEvgeniya Angelova, Charlene Audette, Yelena Kovtun, et al.
American Journal of Hematology|September 28, 2016
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemiasBrittany Knick Ragon, Hagop Kantarjian, Elias Jabbour, et al.
Blood Cancer Journal|May 6, 2020
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemiaIman Abou Dalle, Ahmad Ghorab, Keyur Patel, et al.
Pageof 44

Showing results (221-230 of 436) with videos related to

Sort By:
Pageof 44
American Journal of Hematology|January 23, 2016
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemiaNicholas J Short, Hagop M Kantarjian, Elias J Jabbour, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 15, 2020
Salvage Therapy Outcomes in a Historical Cohort of Patients With Relapsed or Refractory Acute Myeloid LeukemiaFarhad Ravandi, Sherry Pierce, Guillermo Garcia-Manero, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 31, 2014
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemiaAlfonso Quintás-Cardama, Naval Daver, Hawk Kim, et al.
American Journal of Hematology|April 13, 2019
Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blastsPaolo Strati, Guillermo Garcia-Manero, Chong Zhao, et al.
American Journal of Hematology|August 25, 2015
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decadeTalha Badar, Hagop M Kantarjian, Graciela M Nogueras-Gonzalez, et al.
British Journal of Haematology|June 16, 2017
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemiaNicholas J Short, Hagop Kantarjian, Elias Jabbour, et al.
American Journal of Hematology|January 25, 2013
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control studyElias Jabbour, Michael S Mathisen, Guillermo Garcia-Manero, et al.
Haematologica|October 27, 2018
CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemiaEvgeniya Angelova, Charlene Audette, Yelena Kovtun, et al.
American Journal of Hematology|September 28, 2016
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemiasBrittany Knick Ragon, Hagop Kantarjian, Elias Jabbour, et al.
Blood Cancer Journal|May 6, 2020
Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemiaIman Abou Dalle, Ahmad Ghorab, Keyur Patel, et al.
Pageof 44